Lipoatrophy, Fat Accumulation, and Mixed Syndrome in Protease Inhibitor–Naive HIV-Infected Patients
- 1 November 2000
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 25 (3) , 284-286
- https://doi.org/10.1097/00126334-200011010-00014
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndromeAIDS, 2000
- Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* studyAIDS, 2000
- Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophyAIDS, 1999
- Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophyAIDS, 1999
- Inhibition of Adipocyte Differentiation by HIV Protease InhibitorsJournal of Clinical Endocrinology & Metabolism, 1999
- A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapyAIDS, 1999
- Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patientsAIDS, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998